Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 11/20 | 0.58 |
| ▸ | NPC1 | O15118 | 7/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 6/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | CA12 | O43570 | 2/20 | 0.51 |
| ▸ | CA1 | P00915 | 2/20 | 0.51 |
| ▸ | CA2 | P00918 | 2/20 | 0.51 |
| ▸ | CA9 | Q16790 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.49 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | MITF | O75030 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6376711 | 0.86 | MAPT (0.55) | RAB9ANPC1SMN1; SMN2MAPTHTT | |
| SCHEMBL6378062 | 0.85 | RAB9A (0.51) | RAB9ANPC1SMN1; SMN2HPGDALDH1A1 | |
| SCHEMBL6376221 | 0.85 | RAB9A (0.53) | RAB9ANPC1SMN1; SMN2MAPTHTT | |
| SCHEMBL6371005 | 0.82 | RAB9A (0.75) | RAB9ANPC1SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL10816647 | 0.78 | RAB9A (0.71) | RAB9ANPC1SMN1; SMN2HPGDALDH1A1 | |
| SCHEMBL6370838 | 0.76 | FBP1 (0.60) | RAB9ANPC1POLBCA12CA1 | |
| SCHEMBL6371368 | 0.76 | RAB9A (0.53) | RAB9ANPC1MAPTHTTCA12 | |
| SCHEMBL16705130 | 0.75 | ROCK1 (0.70) | RAB9ANPC1SMN1; SMN2ALDH1A1POLB | |
| SCHEMBL6370742 | 0.75 | ADORA3 (0.71) | RAB9ANPC1SMN1; SMN2MAPTPOLB | |
| SCHEMBL5245817 | 0.74 | RAB9A (0.61) | RAB9ANPC1SMN1; SMN2MAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050250816-A1 | Positive allosteric modulators of the nicotinic acetylcholine receptor | PFIZER INC | 2005-11-10 | — | — | US | claimed |
| US-20040254373-A1 | Positive allosteric modulators of the nicotinic acetylcholine receptor | PFIZER INC | 2004-12-16 | — | — | US | claimed |
| US-20030236287-A1 | Positive allosteric modulators of the nicotinic acetylcholine receptor | PHARMACIA & UPJOHN COMPANY | 2003-12-25 | — | — | US | claimed |
| WO-2003093250-A2 | POSITIVE ALLOSTERIC MODULATORS OF THE NICOTINIC ACETYLCHOLINE RECEPTOR | PHARMACIA & UPJOHN COMPANY (US) | 2003-11-13 | — | — | WO | claimed |
| US-20050250816-A1 | Positive allosteric modulators of the nicotinic acetylcholine receptor | PFIZER INC | 2005-11-10 | — | — | US | disclosed |
| US-20040254373-A1 | Positive allosteric modulators of the nicotinic acetylcholine receptor | PFIZER INC | 2004-12-16 | — | — | US | disclosed |
| US-20040249150-A1 | Positive allosteric modulators of the nicotinic acetylcholine receptor | PFIZER INC | 2004-12-09 | — | — | US | disclosed |
| US-20030236287-A1 | Positive allosteric modulators of the nicotinic acetylcholine receptor | PHARMACIA & UPJOHN COMPANY | 2003-12-25 | — | — | US | disclosed |
| WO-2003093250-A2 | POSITIVE ALLOSTERIC MODULATORS OF THE NICOTINIC ACETYLCHOLINE RECEPTOR | PHARMACIA & UPJOHN COMPANY (US) | 2003-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254373-A1 | Positive allosteric modulators of the nicotinic acetylcholine receptor | CHRNA1, CHRNB1, CHRM1 | RAB9A 1449/4885NPC1 1654/4885SMN1; SMN2 1156/4885 |
| US-20030236287-A1 | Positive allosteric modulators of the nicotinic acetylcholine receptor | CHRNA1, CHRNB1, CHRM1 | RAB9A 1449/4885NPC1 1654/4885SMN1; SMN2 1156/4885 |
| US-20040249150-A1 | Positive allosteric modulators of the nicotinic acetylcholine receptor | CHRNA1, CHRNB1, CHRM1 | RAB9A 1449/4885NPC1 1654/4885SMN1; SMN2 1156/4885 |
| US-20050250816-A1 | Positive allosteric modulators of the nicotinic acetylcholine receptor | CHRNA7, CHRNA1, CHRNA5 | RAB9A 921/4885NPC1 2077/4885SMN1; SMN2 1541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.